# The Impact of Nicotinamide Mononucleotide Sustained-release Tablets on Immunosenescence and Metablism in Middle-aged and Elderly Individuals With Metabolic Disorders.

> **NCT06907329** · NA · RECRUITING · sponsor: **Qing Su** · enrollment: 126 (estimated)

## Conditions studied

- Immunosenescence
- Metabolism

## Interventions

- **DIETARY_SUPPLEMENT:** NMN
- **DIETARY_SUPPLEMENT:** Placebo

## Key facts

- **NCT ID:** NCT06907329
- **Lead sponsor:** Qing Su
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-05
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-03-31
- **Target enrollment:** 126 (ESTIMATED)
- **Last updated:** 2025-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06907329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06907329, "The Impact of Nicotinamide Mononucleotide Sustained-release Tablets on Immunosenescence and Metablism in Middle-aged and Elderly Individuals With Metabolic Disorders.". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT06907329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*